SAGE's (SAGE) zuranalone Risk/Benefit Not Very Favorable, Opportunity is Niche - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/20/2022
- Wall Street ends lower as Cisco and Apple sink
- A Recession Could Push S&P 500 to 3360 - Goldman Sachs
- Palo Alto Networks Shares Surge 11% on Q3 Earnings Beat and Raise
- Twitter (TWTR) Says Musk Deal Not 'On-Hold', Won't Renegotiate Price
- After-Hours Stock Movers 05/19: Palo Alto Ramps on Strong Results; Ross Stores Plunges (more...)
- A Recession Could Push S&P 500 to 3360 - Goldman Sachs
- 'Epic Disaster': Tech Bull Daniel Ives Cuts Tesla (TSLA) Stock Price Target by $400 on 'Hard to Ignore' China Lockdowns
- Wall Street ends lower as Cisco and Apple sink
- Magnachip Semiconductor (MX) Offer in Mid-$20s or Above Could Get Deal Done - Oppenheimer
- Deckers Brands (DECK) Announces Resignation of President of Performance Lifestyle
- After-Hours Stock Movers 05/19: Palo Alto Ramps on Strong Results; Ross Stores Plunges (more...)
- Companies with NDRs 5/19
- After-Hours Stock Movers 05/18: Cisco Plunges on Weak Results and Outlook; Synopsys Jumps on Results (more...)
- Pre-Open Stock Movers 05/18: Target Plunges on Weak Results, Outlook; National CineMedia Gains on AMC Stake
- Companies with NDRs 5/18
SAGE Therapeutics (SAGE), Biogen (BIIB) Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
December 1, 2021 6:31 AM ESTSage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorder (MDD) and evaluate the safety and tolerability of zuranolone as well as the need for repeat dosing... More
